Edition:
India

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
20 Apr 2018
Change (% chg)

$-0.01 (-2.96%)
Prev Close
$0.27
Open
$0.27
Day's High
$0.27
Day's Low
$0.25
Volume
12,720
Avg. Vol
165,424
52-wk High
$1.85
52-wk Low
$0.21

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $48.36
Shares Outstanding(Mil.): 78.00
Dividend: --
Yield (%): --

Financials

BRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock

* CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING Source text : [http://bit.ly/2p2XwU7] Further company coverage:

10 Mar 2018

BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population

* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

12 Feb 2018

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017

14 Dec 2017

Earnings vs. Estimates